Navigation Links
Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
Date:6/30/2009

SAN DIEGO, June 30 /PRNewswire/ -- Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company's VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients.

"We are thrilled to have reached the halfway point for enrollment in our GRAVITAS trial," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "Once complete, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved patient outcomes. We continue our commitment to ensuring that the VerifyNow System is shown to be an integral tool in optimizing the use of antiplatelet therapy."

About GRAVITAS

The concept of variability in response to antiplatelet therapy has been well established. Also being demonstrated with increased frequency is the question of whether poor response to antiplatelet therapy, based on a laboratory test, leads to poor patient outcomes. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antip
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
2. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
3. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
4. Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare Reform
5. ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
6. Spherix Announces Positive Phase 2 Study Results
7. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
8. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
9. CoAxia, Inc. Announces $21.5M Series D Financing
10. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
11. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Synapse Biomedical Inc. ( www.synapsebiomedical.com ) ... the post-approval study of its NeuRx DPS® System ... meet the FDA enrollment requirement was implanted over ... The NeuRx DPS®, which is the only medical ... patients, is a humanitarian device that obtained approval ...
(Date:9/30/2014)... Sept. 30, 2014  eHealth, electronic access of ... access of this information, has become a major ... that has not translated into user-friendly, effective products. ... - http://photos.prnewswire.com/prnh/20140929/149123 For ... years developing MWD® Health Manager iEHR, a multilingual ...
(Date:9/30/2014)... Sept. 30, 2014 It is evident from the ... is not performing upto expectations due to the lack of ... with the intake of omega-3 fatty acids. Among omega-3 ingredient ... fish oil, attributed to the large vegetarian population in ... polyunsaturated fatty acid (PUFAs) ingredients is in growth stage of ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... The 2009 Frost & Sullivan European Medical ... the radiology applications market is conferred on Viatronix ... the diagnostic imaging space. , (Logo: ... Viatronix has shown dedication to both developing and ...
... PAC, a leading global provider of advanced analytical instruments ... of the ANTEK MultiTek(TM) testing system for the fast, ... and halides. Industries include BioFuels, Chemicals, Food & Beverage, ... , "MultiTek(TM) is the only instrument on the ...
Cached Medicine Technology:Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 2Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 3Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 4New ANTEK MultiTek(TM) by PAC Provides Fast, All-in-One Testing for Sulfur, Nitrogen, Halides 2
(Date:9/30/2014)... (PRWEB) September 30, 2014 Speaking on ... OMICS Group observed ‘Nursing Conference’ as a remarkable event, ... and medium medical and clinical research and diagnostic companies, ... conference as a perfect platform to share experience, foster ... around the world. Nursing Conference is a forum to ...
(Date:9/30/2014)... 2014 MyMobileUni seeks to partner globally ... have similar shared vision to transform individuals and empower ... (MMU):, , to impact ... all ages , to have focused channels ... to promote equal access to education and ...
(Date:9/30/2014)... bowel cancer for a genetic condition would cut their ... research has found. , In a major study, Dr ... researchers from the University of Exeter,s Medical School assessed ... a genetic condition known as Lynch Syndrome. ... changes in genes which check the spelling in DNA. ...
(Date:9/30/2014)... This two-day, advanced PT continuing ... that may arise following a concussion or mild ... be varied, from sports related injuries, car accidents, falls, ... the thousands of returning soldiers from war zone regions. ... blunt traumas can result in similar injuries, the course ...
(Date:9/30/2014)... Sheridan Healthcare, Inc. , ... today announced that Adam Blomberg, MD, the national ... present at the Society for Healthcare Strategy & ... . The conference will be held October 12-15 ... a four-day conference that draws in more than ...
Breaking Medicine News(10 mins):Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 3Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 2Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 3Health News:Genetic test would help 'cut bowel cancer spread' 2Health News:Genetic test would help 'cut bowel cancer spread' 3Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 3Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 2Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 3
... brain development, the brains first cells neuroepithelial stem cells ... evolves into the various cells of the fully formed brain. ... critical for these stem cells to divide correctly. Without it, ... offers insight into the first steps of brain development, and ...
... QMed, Inc. (Nasdaq:,QMED) today announced financial results for ... Revenue for the year decreased to,$5,246,789 from $8,136,305 a ... $(0.66) per share on a diluted basis, compared to ... basis the previous year.,Revenue for the three-month period ended ...
... hairdressers, barbers , , WEDNESDAY, March 26 (HealthDay News) -- ... had high concentrations of coloring ingredients appear to be ... new report contends. , The authors said the findings ... -- that hair dyes appear to increase the risk ...
... Emergency Medicine is hosting the 11th annual Society of ... Mesa, Calif. As part of the forum, UC Irvine ... variety of related areas ranging from the continued decline ... computerized alcohol-use counseling. , Emergency department ...
... Aging Specialist to Consult with Award-Winning Mind Fitness ... America Conference,Booth #1317) -- CogniFit, Ltd., the company ... software that will enhance human cognitive,performance and health, ... of,Gloria Cavanaugh, long-time president of the American Society ...
... protein, study says. , , WEDNESDAY, March 26 (HealthDay News) -- Keeping ... because it,s harder for women to replace muscle that,s lost naturally ... of 29 healthy women and men, aged 65 to 80, found ... mass -- a key difference in the way women,s and men,s ...
Cached Medicine News:Health News:Key factor in brain development revealed, offers insight into disorder 2Health News:Key factor in brain development revealed, offers insight into disorder 3Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 2Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 3Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 4Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 5Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 6Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 7Health News:Now-Banned Hair Dyes Linked to Bladder Cancer 2Health News:UC Irvine researchers present latest findings at emergency medicine forum 2Health News:CogniFit to Work With Gloria Cavanaugh, Former ASA President 2Health News:Older Women Have Harder Time Preserving Muscle Than Men 2
... this is the universal lithotripter for ... urinary and biliary treatment. The system ... with other applications including cystoscopy, ureteronoscopy, ... system comprises the height adjustable urologist' ...
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
... Reach a new dimension! That of the ... unequalled performance and ease of use. Enjoy ... electroconductive shock wave technology coupled with the ... system. Manage the patient treatment, X-ray and ...
... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
Medicine Products: